Protara Therapeutics, Inc. financial data

Symbol
TARA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
345 Park Avenue South, 3 Rd Floor, New York, New York
Fiscal year end
December 31
Former names
ArTara Therapeutics, Inc. (to 4/23/2020), PROTEON THERAPEUTICS INC (to 12/31/2019)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.23K % -29.5%
Debt-to-equity 14 % +40.1%
Return On Equity -55 % +13.5%
Return On Assets -48.3 % +16.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20.6M shares +82.1%
Common Stock, Shares, Outstanding 11.4M shares +0.5%
Entity Public Float 18M USD -8.16%
Common Stock, Value, Issued 21K USD +90.9%
Weighted Average Number of Shares Outstanding, Basic 21.2M shares +87.8%
Weighted Average Number of Shares Outstanding, Diluted 21.2M shares +87.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 26.7M USD +28.3%
General and Administrative Expense 17.5M USD -7.76%
Operating Income (Loss) -44.3M USD +36.2%
Nonoperating Income (Expense) 3.56M USD +51.1%
Net Income (Loss) Attributable to Parent -40.7M USD +39.3%
Earnings Per Share, Basic -3.19 USD/shares +46.3%
Earnings Per Share, Diluted -3.19 USD/shares +46.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 89.6M USD +164%
Marketable Securities, Current 2.99M USD -95.4%
Other Assets, Current 4K USD +300%
Assets, Current 92.2M USD +9.43%
Property, Plant and Equipment, Net 1.19M USD -17.9%
Operating Lease, Right-of-Use Asset 4.77M USD -17.9%
Goodwill 29.5M USD 0%
Other Assets, Noncurrent 19K USD -99.3%
Assets 102M USD +6.84%
Accounts Payable, Current 1.39M USD -25.2%
Accrued Liabilities, Current 3.23M USD +51.5%
Liabilities, Current 5.65M USD +14.5%
Operating Lease, Liability, Noncurrent 3.95M USD -20.8%
Liabilities 9.6M USD -3.22%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1K USD +99.8%
Retained Earnings (Accumulated Deficit) -221M USD -22.6%
Stockholders' Equity Attributable to Parent 92.1M USD +8.01%
Liabilities and Equity 102M USD +6.84%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.4M USD +19.5%
Net Cash Provided by (Used in) Financing Activities -76K USD -18.8%
Net Cash Provided by (Used in) Investing Activities 23.1M USD +134%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 20.6M shares +82.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 90.3M USD +160%
Deferred Tax Assets, Valuation Allowance 52.7M USD +35.1%
Deferred Tax Assets, Gross 54.3M USD +34.2%
Operating Lease, Liability 4.98M USD -16%
Depreciation 83K USD +7.79%
Payments to Acquire Property, Plant, and Equipment 6K USD -45.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -40.4M USD +39.1%
Lessee, Operating Lease, Liability, to be Paid 5.72M USD -18.8%
Property, Plant and Equipment, Gross 2.12M USD +2.17%
Operating Lease, Liability, Current 1.04M USD +9.06%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.43M USD +7.69%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.4M USD +110%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 737K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43M USD +2.44%
Deferred Tax Assets, Operating Loss Carryforwards 30.7M USD +14.8%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 718K USD -49.8%
Operating Lease, Payments 332K USD 0%
Additional Paid in Capital 313M USD +17.7%
Share-based Payment Arrangement, Expense 5.19M USD -14.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%